For the third quarter of 2026, Wall Street expects Summit Therapeutics to report a net loss of $0.28 per share on zero revenue, with the stock trading at $24.50 relative to an average analyst price target of $29.00. Investors are primarily focused on the company's research and development (R&D) expenditure as it scales global Phase 3 clinical trials for its lead bispecific antibody, ivonescimab.
Following groundbreaking data demonstrating ivonescimab's superiority over pembrolizumab in certain lung cancer trials, the market is seeking specific updates on the U.S. and European regulatory submission timelines. Management’s commentary on the current cash runway, which is intended to support operations through key clinical readouts in 2027, remains a critical component of the Q3 narrative.